Swedish Orphan Biovitrum AB (MEX:SOBI N) Piotroski F-Score: 5 (As of Jul. 29, 2026) — 17% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SOBI N Swedish Orphan Biovitrum AB MEX:SOBI N
87 GF Score
Price MXN523.55
GF Value MXN411.45
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Piotroski F-Score?

Swedish Orphan Biovitrum AB MEX:SOBI N 87 Piotroski F-Score is 5 as of Jul. 29, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates MEX:SOBI N with a GF Score™ of 87/100 and a GF Value™ of MXN411.45. The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 60.65% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Swedish Orphan Biovitrum AB has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Piotroski F-Score or its related term are showing as below:

MEX:SOBI N' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Swedish Orphan Biovitrum AB was 8. The lowest was 4. And the median was 6.

Swedish Orphan Biovitrum AB  (MEX:SOBI N) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Swedish Orphan Biovitrum AB Piotroski F-Score Related Terms


Swedish Orphan Biovitrum AB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Piotroski F-Score Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 5.00 7.00 6.00

Swedish Orphan Biovitrum AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 6.00 6.00 6.00 5.00

MEX:SOBI N vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Piotroski F-Score falls into.


MEX:SOBI N
87GF Score
Swedish Orphan Biovitrum AB MEX:SOBI N
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was -5666.079 + 3605.596 + 2550.884 + 2011.618 = MXN2,502 Mil.
Cash Flow from Operations was 3601.238 + 5775.541 + 2179.283 + 3506.12 = MXN15,062 Mil.
Revenue was 15219.147 + 15152.804 + 13902.126 + 14380.228 = MXN58,654 Mil.
Gross Profit was 12060.235 + 12008.321 + 10522.881 + 11026.308 = MXN45,618 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(135576.077 + 131061.595 + 130650.064 + 157266.465 + 152000.952) / 5 = MXN141311.0306 Mil.
Total Assets at the begining of this year (Jun25) was MXN135,576 Mil.
Long-Term Debt & Capital Lease Obligation was MXN16,016 Mil.
Total Current Assets was MXN31,949 Mil.
Total Current Liabilities was MXN36,510 Mil.
Net Income was 2818.125 + 2652.291 + 1766.632 + 1254.202 = MXN8,491 Mil.

Revenue was 13270.596 + 14117.705 + 13052.884 + 12177.197 = MXN52,618 Mil.
Gross Profit was 10708.489 + 11080.006 + 9846.7 + 9365.102 = MXN41,000 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(127819.71 + 138971.67 + 143235.087 + 141572.811 + 135576.077) / 5 = MXN137435.071 Mil.
Total Assets at the begining of last year (Jun24) was MXN127,820 Mil.
Long-Term Debt & Capital Lease Obligation was MXN17,332 Mil.
Total Current Assets was MXN24,256 Mil.
Total Current Liabilities was MXN24,203 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Swedish Orphan Biovitrum AB's current Net Income (TTM) was 2,502. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Swedish Orphan Biovitrum AB's current Cash Flow from Operations (TTM) was 15,062. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=2502.019/135576.077
=0.01845472

ROA (Last Year)=Net Income/Total Assets (Jun24)
=8491.25/127819.71
=0.06643146

Swedish Orphan Biovitrum AB's return on assets of this year was 0.01845472. Swedish Orphan Biovitrum AB's return on assets of last year was 0.06643146. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Swedish Orphan Biovitrum AB's current Net Income (TTM) was 2,502. Swedish Orphan Biovitrum AB's current Cash Flow from Operations (TTM) was 15,062. ==> 15,062 > 2,502 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=16015.928/141311.0306
=0.11333813

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=17332.046/137435.071
=0.12611079

Swedish Orphan Biovitrum AB's gearing of this year was 0.11333813. Swedish Orphan Biovitrum AB's gearing of last year was 0.12611079. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=31949.338/36509.862
=0.87508789

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=24255.793/24202.548
=1.00219997

Swedish Orphan Biovitrum AB's current ratio of this year was 0.87508789. Swedish Orphan Biovitrum AB's current ratio of last year was 1.00219997. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Swedish Orphan Biovitrum AB's number of shares in issue this year was 350.056. Swedish Orphan Biovitrum AB's number of shares in issue last year was 347.17. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=45617.745/58654.305
=0.77773908

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=41000.297/52618.382
=0.77920102

Swedish Orphan Biovitrum AB's gross margin of this year was 0.77773908. Swedish Orphan Biovitrum AB's gross margin of last year was 0.77920102. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=58654.305/135576.077
=0.4326302

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=52618.382/127819.71
=0.41166094

Swedish Orphan Biovitrum AB's asset turnover of this year was 0.4326302. Swedish Orphan Biovitrum AB's asset turnover of last year was 0.41166094. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Swedish Orphan Biovitrum AB has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Swedish Orphan Biovitrum AB (MEX:SOBI N) has a Piotroski F-Score of 5 as of Jul. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Swedish Orphan Biovitrum AB's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #386 out of 981 companies in the Drug Manufacturers industry, placing it in the top 39.3%.
Is Swedish Orphan Biovitrum AB's Piotroski F-Score too high?
Swedish Orphan Biovitrum AB's current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Swedish Orphan Biovitrum AB's value of 5 is 0% at this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #386 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #386 out of 981 companies for Piotroski F-Score. This puts Swedish Orphan Biovitrum AB in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Swedish Orphan Biovitrum AB's value of 5 is 0% at this benchmark. Historically, Swedish Orphan Biovitrum AB's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Swedish Orphan Biovitrum AB has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Swedish Orphan Biovitrum AB (MEX:SOBI N) has a current Piotroski F-Score of 5. The stock's GF Value™ is MXN411.45, compared to a current price of MXN523.55 — trading 27.2% above its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Drug Manufacturers industry median of 5.00. Swedish Orphan Biovitrum AB's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (MEX:SOBI N), the current Piotroski F-Score is 5 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (MEX:SOBI N) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of MXN523.55 is trading 27.2% above its estimated GF Value™ of MXN411.45.

Key valuation signals for MEX:SOBI N:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: MXN411.45 vs. price of MXN523.55 (27.2% above fair value)
  • GF Score™: 87/100 with 6 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#386 of 981)

No single metric tells the full story. See the MEX:SOBI N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
87GF Score

Get the complete analysis for MEX:SOBI N

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN523.55
Price
MXN411.45
GF Value